Side-by-side · Research reference
PancragenvsTriptorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED23/39 cited
BFDA-ApprovedHUMAN-REVIEWED16/64 cited
01Mechanism of Action
Parameter
Pancragen
Triptorelin
Primary target
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pituitary GnRH receptorsUnknown 2012
Pathway
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
GnRH receptor agonism → initial flare (LH/FSH spike) → receptor desensitization → sustained LH/FSH suppression
Downstream effect
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Castration-level suppression of testosterone (men) and estrogen (women) within 2–4 weeks post-flare
Feedback intact?
Yes — preserves physiological glucose-insulin response
No — bypasses physiological pulsatility; continuous agonism produces paradoxical suppression
Origin
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Synthetic decapeptide analogue of native GnRH with amino acid substitutions for enhanced receptor affinity and stability
Antibody development
—
—
02Dosage Protocols
Parameter
Pancragen
Triptorelin
Primate dose (rhesus macaque)
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
—
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
—
Evidence basis
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Multiple Phase 3 RCTs · FDA-approved 1999
Diabetes model
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
—
1-month depot
—
3.75 mg IM
Most common formulation for prostate cancer.
6-month depot
—
Administration route
—
Intramuscular (IM) — gluteal or deltoid
Indication: Prostate cancer
—
Advanced (metastatic or locally advanced)
Androgen deprivation therapy (ADT) backbone.
Indication: Endometriosis
—
3.75 mg monthly
FDA-approved; typically 6-month course.
Indication: Central precocious puberty
—
Pediatric use (≥2 years)Jia 2025
Weight-based dosing per FDA label.
Duration (prostate cancer)
—
Continuous or intermittent ADT protocolsPreston 2024
Intermittent ADT may reduce side effects; cardiovascular risk similar to continuous.
Monitoring
—
Serum testosterone, PSA (prostate cancer), bone density, lipids, glucose
04Side Effects & Safety
Parameter
Pancragen
Triptorelin
Reported adverse events
None documented in primate studies
—
Human safety data
No published human trials; clinical use limited to Russian gerontology protocols
—
Initial flare symptoms
—
Bone pain, urinary obstruction, spinal cord compression (first 2 weeks)
Antiandrogen co-treatment (bicalutamide) mitigates flare in metastatic disease.
Cardiovascular events
—
MI, stroke, arrhythmia — GnRH agonists show higher CV risk vs antagonists in meta-analysesPatel 2025Preston 2024
Hot flashes
—
Very common (>60%); vasomotor instability
Bone loss / Osteoporosis
—
Accelerated bone mineral density decline; fracture risk ↑Friedrich 2025
Baseline DEXA scan recommended; bisphosphonates or denosumab may be indicated.
Metabolic syndrome
—
Weight gain, insulin resistance, dyslipidemia, diabetes risk
Injection site reactions
—
Pain, erythema, sterile abscess (rare with depot formulations)
Gynecomastia / Breast tenderness
—
Common (10–20%); peripheral aromatization of residual androgens
Fatigue / Mood changes
—
Anemia, depression, cognitive changes reported in long-term ADT
Hepatotoxicity
—
Transient transaminase elevations; clinically apparent liver injury rare
Racial differences (ADT)
—
Black veterans show higher CV event rates vs White veterans on GnRH agonists
Absolute Contraindications
Pancragen
—Triptorelin
- ·Hypersensitivity to triptorelin, GnRH, or GnRH agonist analogues
- ·Pregnancy (Category X)
Relative Contraindications
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
Triptorelin
- ·Active cardiovascular disease — consider GnRH antagonist alternative
- ·Metastatic vertebral disease with spinal cord compression risk (flare hazard)
- ·Severe urinary obstruction — may worsen during flare
- ·Osteoporosis or high fracture risk (requires bone-protective therapy)
05Administration Protocol
Parameter
Pancragen
Triptorelin
1. Reconstitution
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
Choose 1-month (3.75 mg), 3-month (11.25 mg), or 6-month (22.5 mg) depot based on adherence needs and clinical context. 6-month formulation shows improved real-world adherence in Asia-Pacific cohorts.
2. Route
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
Intramuscular — gluteal or deltoid muscle. Use 21–23G needle. Aspirate to confirm non-vascular placement. Rotate sites with repeat injections.
3. Timing
No specific timing constraints documented. Administered once daily in primate protocols.
For metastatic prostate cancer: co-administer antiandrogen (e.g., bicalutamide 50 mg daily) starting 1 week before first injection and continuing 2–4 weeks to prevent tumor flare.
4. Cycle structure
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
Baseline: testosterone, PSA, bone density (DEXA), lipids, glucose. Follow-up: testosterone at 4 weeks (confirm <50 ng/dL castration), PSA monthly × 3, then quarterly. Annual DEXA for bone loss.
5. Storage
—
Store vials at room temperature (20–25 °C), protect from light. Do not freeze. Reconstituted suspension should be used immediately.
6. Intermittent ADT protocol (optional)
—
Some protocols use on-treatment periods (9–12 months) alternating with off-treatment intervals until PSA rises. Cardiovascular risk appears similar to continuous ADT.